Market news

Moderna shares are climbing again Tuesday, touching a new 52-week high of $208.90 on continued momentum from strong clinical trial news.

Moderna stock is near the bull-case range, but the central-case implies downside. Click here to read this latest analysis of MRNA.

Delaware judge lets Monsanto’s mRNA patent lawsuits vs Pfizer, BioNTech, and Moderna proceed. Read more here.

Detailed price information for Netflix Inc (NFLX-Q) from The Globe and Mail including charting and trades.

Moderna has the clinical lead, while BioNTech has the deeper war chest. See which cancer stock offers the stronger long-term setup as mRNA oncology enters a new phase.

Laidlaw analyst Yale Jen flagged possible data in other cancers from 2027, while warning that personalized manufacturing costs, capacity and reimbursement could limit commercial success.

In recent weeks, Moderna and Merck reported that their Phase 3 INTerpath-001 trial of personalized cancer vaccine intismeran autogene plus Keytruda met its primary endpoint in melanoma, with full data presented earlier this month at the European Society for Medical Oncology Congress 2026 and accompanied by growing oncology-focused pipeline visibility. At the same time, Moderna’s talks with Middle East partners about potential investment and manufacturing cooperation highlight how its mRNA...

Moderna (NasdaqGS:MRNA) entered high-level investment talks with the UAE government on advanced pharmaceutical manufacturing and R&D collaboration. The discussions focus on expanded research capabilities, potential local production, and broader access to Middle Eastern healthcare markets. Management framed the UAE engagement as part of a wider push to build out Moderna's international footprint beyond existing Western partnerships. The UAE collaboration talks matter, but investors also need...

Moderna (MRNA) concluded the recent trading session at $198.88, signifying a +2.08% move from its prior day's close.

Moderna Inc. (NASDAQ: MRNA) shares are trading higher Friday, hitting a fresh 52-week high on anticipation of clinical trial data.

Key TakeawaysOncology Repricing: Moderna stock jumped 7% on Thursday, September 24, closing at $195 as investors kept betting on intismeran autogene’s Phase 3 melanoma data due at ESMO on October 24. Street Split: The 23 analysts covering Moderna stock are split 4 buys, 1 outperform, 16 holds, 1 underperform, and 1 sell, with a mean target of $120 that sits 39% below Thursday’s close.

Moderna shares rose 0.09% after hours Thursday as investors eyed upcoming oncology data at a major European conference.

Moderna Inc. (NASDAQ:MRNA) saw its share price climb to a new four-year high on Thursday, as investors cheered news that it was exploring investment opportunities in the Middle East. In intra-day trading, the stock climbed to a record high of $195.71 before trimming gains to finish the session just up by 6.98 percent at $194.82 […]

Moderna (NASDAQ:MRNA) executives emphasized the company’s evolution beyond COVID-19 vaccines during a discussion with Bernstein, highlighting its mRNA platform, personalized cancer vaccine program intismeran, rare-disease pipeline and plans to expand therapeutics development. Chief Executive Office

Moderna has delivered a very large 1 year share price gain, which puts fresh attention on a basic question. Is the current valuation of the stock supported by the company’s sales profile rather than just recent momentum and headlines? The stock is up a very large amount over the past 12 months, which makes the link between Moderna’s market value and its underlying sales more important for anyone thinking about valuation risk. News around mRNA products, from the mFlusiva flu vaccine launch to...

Moderna has surged over 500% this year while its closest messenger RNA rival sits nearly flat, and a single late-October data presentation at ESMO could either cement the rally or erase it overnight.

Thermo Fisher, Moderna and Agilent show overbought RSI readings above 70, warning momentum-focused investors of potential near-term weakness.

Moderna's 52-week high follows positive melanoma results, with detailed phase III data set for an ESMO presentation.

Key TakeawaysPresidential Symposium Slot: Moderna stock jumped 12% to $173 on September 21 after Phase 3 melanoma data for its cancer vaccine, intismeran autogene, earned a spot in ESMO’s Presidential Symposium on October 24. Vaccine Clearance: The FDA cleared updated Spikevax and mNEXSPIKE shots targeting the JN.

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 9.4% in the afternoon session after positive Phase 3 INTerpath-001 trial results evaluating its personalized cancer vaccine, intismeran autogene, alongside Merck's Keytruda in high-risk melanoma patients continued to drive momentum.

Moderna will showcase detailed melanoma results for Intismeran at ESMO, alongside data and trial updates exploring the personalized therapy in pancreatic and lung cancers.

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often

Moderna shares are surging Monday. The company announced three intismeran autogene abstracts were accepted for presentation at ESMO Congress.

Detailed price information for Moderna Inc (MRNA-Q) from The Globe and Mail including charting and trades.

Detailed price information for Moderna Inc (MRNA-Q) from The Globe and Mail including charting and trades.

A coveted Presidential Symposium slot at Europe's top oncology congress just sent Moderna shares flying 9%, but the actual Phase 3 melanoma data remains unseen. Here is why the scheduling alone is moving markets and what it signals about what that dataset might show.

The presentation details are as follows:Presidential Symposium: * LBA1- INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL) Session Type/Title: Presidential Symposium Date & Time: Saturday, October 24, 4:30 PM CEST / 10:30 AM EDT Presenter: Georgina V. Long (Sydney, Australia, NSW)Poster Presentations: * Abstract 3151P: Adj

CI is pairing top AI and biotech minds on its board (plus an advisory role for OpenAI's Fidji Simo) as it tests models on a Novo Nordisk drug.

Trials investigating mRNA vaccines for lung cancer, pancreatic cancer and other diseases are already underway.

Moderna (MRNA) has been back in the spotlight after its appearance at the Morgan Stanley Global Healthcare Conference, where management highlighted progress across its vaccine portfolio and ongoing Phase 3 work on personalized cancer candidate intismeran. Recent trading has been volatile for Moderna, with a 1-day share price return that declined 2.55% after the latest close at US$154.04. However, a 7-day share price return of 6.99% and a 90-day gain of 140.84% indicate upward momentum that...

Nasdaq rises for week but Dow and Russell 2000 are notable losers.